FDA approved first adjuvant therapy for most common type of lung cancer
On Dec. 18, 2020, the FDA approved AstraZeneca’s Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Tags:
Source: U.S. Food and Drug Administration
Credit:
